Request Demo

Last update 23 Jan 2025

Transitional cell cancer of renal pelvis and ureter metastatic

Last update 23 Jan 2025

Basic Info

Synonyms

Malignant neoplasm of renal pelvis and ureter metastatic transitional cell, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Transitional Cell Cancer of Renal Pelvis and Ureter

+ [17]

Introduction

A urothelial carcinoma of the renal pelvis and ureter that has spread from its original site of growth to another anatomic site.

Drugs associated with Transitional cell cancer of renal pelvis and ureter metastatic

Tremelimumab

Target

CTLA4

Mechanism

CTLA4 inhibitors

Active Org.

AstraZeneca PLC [+12]

Originator Org.

AstraZeneca AB [+1]

Active Indication

Hepatocellular Carcinoma [+78]

Inactive Indication

Advanced cancer [+54]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date21 Oct 2022

Atezolizumab

Target

PDL1

Mechanism

PDL1 inhibitors

Active Org.

Roche Registration GmbH [+26]

Originator Org.

Genentech, Inc. [+1]

Active Indication

Advanced Lung Non-Small Cell Carcinoma [+160]

Inactive Indication

Acute Myeloid Leukemia [+59]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date18 May 2016

Afatinib Dimaleate

Target

EGFR x EGFR L858R x EGFR-Ex19del x HER2 x HER4

Mechanism

EGFR antagonists [+4]

Active Org.

Boehringer Ingelheim GmbH [+5]

Originator Org.

C.H. Boehringer Sohn AG & Co. KG

Active Indication

Squamous non-small cell lung cancer [+19]

Inactive Indication

Adenocarcinoma of Lung [+44]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date12 Jul 2013

Clinical Trials associated with Transitional cell cancer of renal pelvis and ureter metastatic

EUCTR2018-003027-11-IT

/ Not yet recruitingPhase 2IIT

A prospective, multi-center, open-label, single-arm, two- step phase II study of DURvalumab (MEDI4736) in patients WIth poor performance status as first-liNe treatment for advanced urothelial cancer: the DURWIN trial - DURWIN

Start Date16 May 2019

Sponsor / Collaborator

Consorzio Oncotech

EUCTR2017-000579-10-IT

/ Not yet recruitingPhase 2IIT

An open label, single-arm, phase 2 study of pembrolizumab and nanoparticle albumin-bound paclitaxel in patients with metastatic urothelial carcinoma after chemotherapy failure; the PEANUT study - Pembrolizumab and abraxane in locally advanced metastatic urothelial carcinoma after chemotherapy fa

Start Date20 Mar 2019

Sponsor / Collaborator

Fondazione Irccs Istituto Nazionale Dei Tumori

NCT03430895

/ CompletedPhase 2IIT

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

Start Date31 Jan 2018

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+1]

100 Clinical Results associated with Transitional cell cancer of renal pelvis and ureter metastatic

100 Translational Medicine associated with Transitional cell cancer of renal pelvis and ureter metastatic

0 Patents (Medical) associated with Transitional cell cancer of renal pelvis and ureter metastatic

Literatures (Medical) associated with Transitional cell cancer of renal pelvis and ureter metastatic

01 Oct 2024·Clinical Genitourinary Cancer

Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study

Article

Author: Seki, Narihito ; Kiyoshima, Keijiro ; Masaoka, Hiroyuki ; Negishi, Takahito ; Harada, Kenichi ; Tomisaki, Ikko ; Tomoda, Toshihisa ; Hori, Yoshifumi ; Fujimoto, Naohiro ; Kuroiwa, Kentaro ; Minato, Akinori ; Nakamura, Motonobu ; Furubayashi, Nobuki ; Song, Yoohyun

INTRODUCTIONTo evaluate the organ-specific therapeutic effect of enfortumab vedotin (EV) after chemotherapy and immunotherapy failed for advanced urothelial carcinoma.MATERIALS METHODSAt 6 institutions between December 2021 and July 2023, we retrospectively analyzed patients with metastatic upper and lower urinary tract cancer who received EV monotherapy after platinum-based chemotherapy and immune checkpoint blockade therapy. Objective response rate (ORR) and organ-specific response rate (OSRR) were evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.RESULTSThis study analyzed 58 patients with 210 tumor lesions, of which 24% were females and 48% had upper urinary tract cancer. The ORR and disease control rate were 53.5% and 74.1%. Moreover, we found 15 target lesions in the primary site, 7 in local recurrence, 93 in the lymph nodes, 46 in the lung, 29 in the liver, and 20 in the bone, with OSRRs of 40%, 71.4%, 61.1%, 70.6%, 90.9%, and 18.2%, respectively. Over time from baseline, the reduction rate (median) in tumor burden was 50% or more in the lymph node, lung, and liver metastases.CONCLUSIONThe organ-specific tumor response to EV in patients with metastatic urothelial carcinoma was almost favorable. The antitumor activity of EV monotherapy may be less in bone metastasis than in other organ sites. Conversely, EV showed remarkably high efficacy against liver metastasis.

01 Jun 2024·Translational Andrology and Urology

Efficacy of cytoreductive surgery for metastatic upper tract urothelial carcinoma: a Surveillance, Epidemiology and End Results (SEER) study of 508 patients

Article

Author: Wang, Mingrui ; Lai, Shicong ; Hu, Haopu ; Xu, Tao ; Ni, Runfeng ; Lai, Chinhui ; Hu, Hao ; Ji, Jiaxiang

BackgroundCisplatin-based combination chemotherapy alone is currently considered the standard of care for patients with metastatic upper tract urothelial carcinoma (mUTUC). However, less research has been done on the efficacy of other combinations. In this study, we explored the role of cytoreductive surgery in patients with mUTUC receiving different types of systemic therapy.MethodsData from 9,436 anonymized records were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database between 2008-2018. Of these, 508 individuals received systemic therapy subsequent to being diagnosed with mUTUC. These patients had all been treated with systemic therapies such as chemotherapy and/or radiotherapy. Patients were stratified into either a non-surgical or surgical group based on cytoreductive surgery status before systemic therapeutics commenced. Kaplan-Meier curves were used to compare overall survival (OS) and cancer-specific survival (CSS). Cox's proportional hazard models were then used to analyze prognostic factors related to OS and CSS.ResultsOf the 508 cases, 36.8% (n=187) had received cytoreductive surgery with systemic treatments. The remaining 63.2% (n=321) received either chemotherapy and/or radiotherapy alone. Kaplan-Meier curves showed that 11.6% had 3-year OS [95% confidential interval (CI): 7.1-17.3] for cytoreductive surgery with systemic treatment and 4.9% (95% CI: 2.7-8.0) for systemic treatment alone (P=0.001). The 3-year CSS was 14.9% for cytoreductive surgery plus systemic treatment (95% CI: 9.4-21.7%) and 6.0% (95% CI: 3.4-9.8%) for systemic treatments alone (P=0.003). Under multivariate regression analysis, primary ureter site OS had a hazard ratio (HR) of 0.74 (95% CI: 0.58-0.95, P=0.02) and a CSS HR of 0.72 (95% CI: 0.56-0.94, P=0.01). The cytoreductive surgery OS HR was 0.79 (95% CI: 0.65-0.95, P=0.02) and the CSS HR was 0.75 (95% CI: 0.61-0.92, P=0.006). Additionally, chemotherapy had an OS HR of 0.46 (95% CI: 0.33-0.0.65, P<0.001) and a CSS HR of 0.44 (95% CI: 0.31-0.63, P<0.001). Bones and liver metastases were also indicative of poorer prognosis. Validation was conducted through subgroup analysis which suggested cytoreductive surgery was effective only for patients who received chemotherapy or combined chemo-radiotherapy but not for radiotherapy alone.ConclusionsCytoreductive surgery provided significantly increased OS and CSS for mUTUC patients who received chemotherapy or combined chemo-radiotherapy in this study. In addition, the primary tumor and metastatic sites were shown to be related to improved patient survival although this was a small and relatively homogeneous cohort of study, sample therefore, further research is required.

01 Jun 2024·Diagnostic Cytopathology

Metastatic upper tract urothelial carcinoma with nest‐like features presenting as malignant pleural effusion

Article

Author: Ricci, Paolo ; Valenti, Alessandra ; Ascoli, Valeria ; Arienzo, Francesca

AbstractMetastatic urothelial carcinoma is a rare cause of pleural effusions. We report a case of urothelial carcinoma of the upper urinary tract in an oldest‐old male patient, a smoker, with situs inversus totalis, that presented uniquely with malignant pleural effusion at presentation without evidence of a primary tumor on imaging. Cytological smears of the massive left pleural effusion revealed epithelioid neoplastic cells arranged in short cords, small‐to‐large clusters, and raspberry‐like morules, mimicking mesothelioma; cell block preparations highlighted the presence of tubules and nest‐like structures. The tumor cells showed a high nuclear‐to‐cytoplasmic ratio, nuclear grooves, and mitotic figures. Cytomorphologic features coupled with the immunophenotype of neoplastic cells (p63, GATA3, and uroplakin II positive) allowed the diagnosis of metastatic urothelial carcinoma and a possible nested subtype. These findings were supported by a total body computed tomography (CT) showing no evidence of a mass in the bladder or elsewhere in the urinary tract but a concentric parietal thickening of the proximal left ureter, suggesting malignancy. To our knowledge, a malignant effusion as a primary manifestation of urothelial carcinoma with nest‐like features originating in the upper urinary tract has never been described previously. Our case focuses on the value of cell block in the working‐up of neoplastic effusions by revealing the architectural pattern of an uncommon malignancy and the correlation between cytopathology and imaging gross findings to reach an accurate diagnosis.

News (Medical) associated with Transitional cell cancer of renal pelvis and ureter metastatic

14 Jun 2017

·www.bioportfolio.com

Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 Pipeline Review, H1 2017 [Updated: 13062017] Prices from USD $3500

Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 Pipeline Review, H1 2017 Summary Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 Pipeline Review, H1 2017, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal downregulation of the expression of CYP7A1, the ratelimiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in PreRegistration, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 5, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer Cholangiocarcinoma, Type 2 Diabetes, Breast Cancer, Esophageal Cancer, Gastric Cancer, Lung Adenocarcinoma, Lymphoma, Melanoma, NonAlcoholic Steatohepatitis NASH, NonSmall Cell Lung Cancer, Obesity, Ovarian Cancer, Recurrent Glioblastoma Multiforme GBM, Adrenocortical Carcinoma Adrenal Cortex Cancer, Chronic Lymphocytic Leukemia CLL, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosis, Glioblastoma Multiforme GBM, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Transitional Urothelial Tract Cancer, Nasopharyngeal Cancer, NonSmall Cell Lung Carcinoma, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, SmallCell Lung Cancer, Spinal Cord Injury, Thymic Carcinoma, Thyroid Cancer and Transitional Cell Cancer Urothelial Cell Cancer. Furthermore, this report also reviewsalso reviews key players involved in Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 The report reviews Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities The report reviews key players involved in Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects The report assesses Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 targeted therapeutics Reasons to buy Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 CD334 or FGFR4 or EC 2.7.10.1 development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Acquisition

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Transitional cell cancer of renal pelvis and ureter metastatic

Basic Info

Related

Analysis